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ORIGINAL ARTICLE
Label-free, live optical imaging of reprogrammed bipolar
disorder patient-derived cells reveals a functional correlate of
lithium responsiveness
JL Wang
1,2,3, SM Shamah
4, AX Sun
5, ID Waldman
6, SJ Haggarty
1,2,3,7 and RH Perlis
1,2,3
Development of novel treatments and diagnostic tools for psychiatric illness has been hindered by the absence of cellular models
of disease. With the advent of cellular reprogramming, it may be possible to recapitulate the disease biology of psychiatric disorders
using patient skin cells transdifferentiated to neurons. However, efﬁciently identifying and characterizing relevant neuronal
phenotypes in the absence of well-deﬁned pathophysiology remains a challenge. In this study, we collected ﬁbroblast samples from
patients with bipolar 1 disorder, characterized by their lithium response (n=12), and healthy control subjects (n=6). We identiﬁed a
cellular phenotype in reprogrammed neurons using a label-free imaging assay based on a nanostructured photonic crystal
biosensor and found that an optical measure of cell adhesion was associated with clinical response to lithium treatment. This
cellular phenotype may represent a useful biomarker to evaluate drug response and screen for novel therapeutics.
Translational Psychiatry (2014) 4, e428; doi:10.1038/tp.2014.72; published online 26 August 2014
INTRODUCTION
Bipolar disorder (BD) is a debilitating psychiatric condition
characterized by periods of elevated or irritable mood and
depression.
1,2 Since its serendipitous discovery over 50 years
ago, lithium remains the gold-standard treatment for long-term
management of BD.
3 However, lithium only beneﬁts a subset of
individuals with this illness.
4
There is thus a pressing need for better therapeutics, as well as
diagnostic tools which might predict patient drug response. The
challenge has been identifying a distinct cellular pathophysiology
associated with the disorder. Investigators have generally been
limited to the study of peripheral blood cells or postmortem brain
samples, each of which presents limitations, both in determining
relevance to the neurobiology of BD and in deriving cellular
models which scale for screening applications and diagnostic
development.
Recent developments in reprogrammed adult human cells
make it possible to derive neuronal cells directly from more
accessible patient tissues, either through an induced pluripotent
stem cell intermediate
5–7 or via direct transdifferentiation of
human ﬁbroblasts to neurons.
8–10 These reprogrammed cellular
models have been demonstrated to recapitulate disease pathol-
ogy observed in primary human brain cells for neurodegenerative
disorders such as Alzheimer’s disease and Parkinson’s disease.
11
Efﬁciently identifying and characterizing relevant neuronal phe-
notypes in the absence of well-deﬁned pathophysiology remains a
challenge. Here, we hypothesized that lithium response in BD
patients would have a measurable cellular correlate in patient
ﬁbroblast lines directly transdifferentiated to neurons using a
high-throughput, label-free imaging platform.
In this label-free cellular assay, the signal generated is a
measure of adhesion of the cell to the imaged surface, mediated
by cell surface integrins and extracellular matrix components
coated on the surface of biosensors. Once adhered to the
biosensors, cells respond to a wide variety of stimuli that result in
the modulation of cell adhesion mediated by changes in the
activation state of integrins through a process referred to as
‘inside-out signaling’.
12 These changes can be measured and
quantiﬁed with high sensitivity and serve the basis of functional
cell-based assays for identifying compounds that can modulate
speciﬁc ligand–receptor signaling pathways.
13,14 The BIND Scan-
ner used in our experiments has sufﬁciently high spatial and
temporal resolution that single cell morphologies can be
segmented and a number of cellular phenotypes quantiﬁed,
including cell migration, membrane rufﬂing, mitotic events,
apoptosis, proliferation and immune cell activation.
14 This makes
the platform particularly advantageous for characterizing disease-
associated cellular phenotypes, which may be applied for high-
throughput screening or diagnostic efforts. In our study, we
examined changes in cell count, cell fraction, cell perimeter and
peak wavelength value (PWV), which is a measure of the
attachment of the cells to the surface. We found that changes
in PWV were associated with patient lithium response in
ﬁbroblasts transdifferentiated to neuronal-like cells.
MATERIALS AND METHODS
Patient sample collection
Skin samples from a convenience sample of patients with bipolar 1
disorder and a history of lithium treatment (n=12) and matched screened
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informed consent as part of a protocol approved by the Partners
Institutional Review Board. All subjects were evaluated using the structured
clinical interview for DSM-IV (SCID-I) conducted by an experienced
psychiatrist. Lifetime lithium response was deﬁned by clinical interview
and review of all available records using the Alda scale for long-term
treatment response in research subjects with bipolar disorder,
15 which
assigns a 0–10 score (‘Criterion A’) for clinical improvement during lithium
treatment compared with time not treated with lithium, in terms of
episode frequency, severity and duration. On this scale, 10 indicates full
and sustained remission with lithium treatment, whereas 0 indicates no
change or clinical worsening. This scale, although retrospective, has been
shown to be a reliable and valid summary measurement of lithium
responsiveness. As the utility and weighting of the B criteria, relating to
features such as compliance, is less clear,
16 we selected extreme cases
based upon A criteria, excluding individuals who were nonadherent with
lithium based upon the relevant B criterion. We grouped BD patients into a
lithium responsive group if the Alda score was 7–10, and lithium
nonresponsive if the Alda score was 1–4.
Clinical procedures
After informed consent was obtained and clinical interview was completed
to conﬁrm eligibility, a dermal biopsy was obtained by a physician
investigator. Following subcutaneous injection of lidocaine 1%, the
physician used a standard 3.0 or 4.0mm punch tool to obtain a sample
from the medial surface of the nondominant forearm. Fibroblasts were
then expanded using standard tissue culture technique.
Lentivirus production
High-titer lentiviral stocks were generated using 293T/17 cells (ATCC,
Manassas, VA, USA). Cells were plated on poly-L-Lysine (Sigma, St. Louis,
MO, USA) coated tissue culture vessels and grown to 95% conﬂuence in
D10 medium containing Dulbecco’s Modiﬁed Eagle Medium (Invitrogen,
Carlsbad, CA, USA) with 10% fetal bovine serum (Gemini Bio-Products,
West Sacramento, CA, USA) and 1% Pen-Strep (Invitrogen), then
transfected with lentiviral packaging plasmids pCMV2dR8.2 (Addgene
plasmid 8455, Cambridge, MA, USA)
17 and pMD2.G (Addgene plasmid
12259) and one of the lentivectors containing transgenes for miR-9/9*-124,
NEUROD2, ASCL1 or MYT1L using Lipofectamine 2000 (Invitrogen) in
Optimem (Invitrogen). After 4–6h, the medium was changed back to D10
medium, collected after 48h and ultracentrifuged at 19500r.p.m. for 2h to
make high-titer lentiviral stocks.
Induced neuronal-like cells
Fibroblasts were transduced with lentiviruses containing transgenes for
miR-9/9*-124, NEUROD2, ASCL1 and MYT1L as previously described.
9
Fibroblasts were plated at a density of 10–15k cm
−2 in ﬁbroblast medium
(Dulbecco’s Modiﬁed Eagle Medium; Invitrogen) containing 10% fetal
bovine serum (FBS; Gemini Bio-Products), nonessential amino acids,
glutamate and penicillin/streptomycin (Invitrogen) on plates coated with
0.1% gelatin (Millipore, Billerica, MA, USA). Fibroblast medium contained
DMEM (Invitrogen) with 10% FBS (Gemini Bio-Products), 1% Pen-Strep
(Invitrogen, Grand Island, NY, USA), 1% non-essential amino acids
(Invitrogen) and 1% 200mM L-glutamine (Invitrogen). Infection with the
four lentiviruses occurred 24h after plating using 8 µgml
−1 polybrene
(Sigma) with plates centrifuged at 1000g for 20min to enhance the
lentivirus infection efﬁciency. The next day, medium was changed to
ﬁbroblast medium containing 1mM valproic acid (Sigma), and 3 days later,
the medium was changed to Neuronal Medium (ScienCell, Carlsbad, CA,
USA) containing 1mM valproic acid along with selection antibiotics
Geneticin, Blasticidin and Puromycin (all Invitrogen). Selection antibiotics
were removed after 6–7 days, and the cells were maintained in Neuronal
Medium (ScienCell) with 1 mM valproic acid for 1–3 days until passaging
with Accutase (Sigma) onto a 384-well BIND biosensor.
BIND imaging
BIND biosensors used for induced neuronal-like cell (iNLC) imaging were
coated with 20µgml
−1 poly-ornithine (Sigma) and 20µgml
−1 laminin
(Sigma) and biosensors used for ﬁbroblast imaging were coated with
2.5µgml
−1 ﬁbronectin (BD Biosciences, San Jose, CA, USA). iNLCs were
seeded at 1000 cells per well, and human ﬁbroblasts were seeded at 200
cells per well. Biosensors were blocked with 1% bovine serum albumin
(Sigma) in Dulbecco’s phosphate-buffered saline (dPBS, Invitrogen) before
plating cells to minimize background. After seeding cells, the biosensor
was brieﬂy centrifuged at 1000r.p.m. for 10s to ensure that the cells were
contacting the biosensor. The biosensor was equilibrated at 37ºC for
15–30min before imaging. Time-lapse BIND images were collected using
BIND Scan software.
Immunocytochemistry
At the same time point and density that iNLCs were plated on BIND
biosensors, they were plated on poly-ornithine/laminin coated 384-well
plates for immunocytochemistry. Corresponding ﬁbroblast lines were
seeded at 1000 cells per well in 384 well plates. One day later, cells were
ﬁxed in 4% formaldehyde (Tousimis) in dPBS for 30min at 25ºC, rinsed
three times in PBS, and then incubated overnight at 4ºC with primary
antibodies against Fibroblast (1:10, Miltenyi Biotec, Bergisch Gladbach,
Germany), FSP1/S100A4 (1:750, Millipore), VIM (1:50, Abcam, Cambridge,
UK), SOX2 (1:200, Abcam), NES (1:500, Millipore), MAP2 (1:5000, EnCor
Biotechnology CPCA-MAP2, Gainesville, FL, USA), TUBB3 (1:5000, Sigma
T8660) and SYN1 (1:200, Cell Signaling, Danvers, MA, USA) in a blocking
solution containing 0.1% Triton, 5% normal goat serum (Invitrogen) and
0.1% gelatin (Sigma) in dPBS. Cells were rinsed ﬁve times with dPBS, then
incubated for 1h at 25ºC with an Alexa Fluor 488 secondary antibody
corresponding to the primary (1:500, Invitrogen A-11039, A-11034 and
A-11029) in the same blocking solution containing NucBlue Hoechst 33342
(Life Technologies, Grand Island, NY, USA) to label cellular nuclei. Cells were
rinsed three times in dPBS, and images were acquired using an INCell 6000
(GE Healthcare, Piscataway, NJ, USA). Images were rescaled and
pseudocolored using Fiji for display purposes with the same range used
for each antibody across both cell types.
Data analysis
BIND Scan data was segmented and cellular metrics quantiﬁed using BIND
View software. Background leveling was implemented with a 17-pixel
structural morphological parameter. Segmented objects were classiﬁed as
cells if they had a PWV minimum of 0.2–0.35nm and a maximum of 5nm
above background and had an area greater than 10 pixels. A local
background area around each segmented cell was calculated from a 2-
pixel radius located 3 pixels outside the boundary of the cell. The average
PWV from this local background area was subtracted from the average
PWV inside the boundary of the cell to calculate the cellular PWV metric.
Cell count, cell fraction and cell perimeter were computed from the mask
of the segmented cells. These metrics were exported for each image in the
time-lapse series and comprised the time series data in Figure 1b. Delta
metrics were calculated as:
Δmetric ¼
metric1:5h -metricbaseline
metricbaseline
GLMs utilized the 'glm' command in Stata 13 (StataCorp, College Station,
TX, USA) with default settings for family (Gaussian) and link function
(identity), and observations clustered within patients. Including within-
plate clustering as well, rather than covarying for plate, did not yield
meaningfully different results.
RESULTS
Generation of iNLCs
Skin samples from a clinically phenotyped cohort of patients with
bipolar 1 disorder and a history of lithium treatment (n=12) and
matched screened healthy control subjects (n=6) were expanded
into ﬁbroblast lines and subsequently transformed using recom-
binant lentiviruses carrying transgenes for miR-9/9*-124, NEU-
ROD2, ASCL1 and MYT1L.
9 This transformation results in iNLCs,
directly transdifferentiated from the starting ﬁbroblast population.
The full duration of time to generate ‘mature’ neuronal-like cells
that express synaptic markers and ﬁre action potentials as
described by Yoo et al.
9 is 4–5 weeks. However, due to reduced
viability we observed over this prolonged time period of
differentiation, and the goal of a more rapid screening process,
we elected to measure cellular activity at an earlier time point in
the transdifferentiation process to facilitate generating reprodu-
cible measurements over larger numbers of iNLCs. This period,
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cells expressing the transgenes, but before the large amount of
cellular attrition. Figure 2a shows the timeline of the neural
induction.
At this time point, cells are undergoing large morphological
changes reminiscent of axonogenesis and dendritogenesis in
rodent neurons. We performed immunocytochemistry to char-
acterize the iNLCs along with the source patient ﬁbroblast line. We
selected a panel of antibodies to label ﬁbroblasts (anti-Fibroblast),
ﬁbroblasts and neural stem cells (S100A4, VIM), neural stem cells
only (NES, SOX2) and neurons (MAP2, TUBB3, SYN1). Images for a
representative control line are shown in Supplementary Figure 1.
Anti-Fibroblast labeled both ﬁbroblasts and iNLCs. In addition,
both ﬁbroblasts and iNLCs expressed S100A4 and VIM. Expression
of markers for neural stem cells only and neurons was present in
iNLCs, but not ﬁbroblasts. These results suggest that iNLCs are an
intermediate cell type, expressing markers for both neural stem
cells and neurons. Although iNLCs still express ﬁbroblast markers,
they differ from ﬁbroblasts by expression of neuronal markers.
BIND imaging reveals metrics associated with iNLC growth
After 13–14 days of differentiation, we replated iNLCs on a BIND
biosensor consisting of an array of individual biosensor wells in a
standard 384-well plate reader format (Figure 2b). BIND biosensors
consist of polymer surfaces embossed with grating structures of a
precise and uniform periodicity and coated with titanium dioxide.
When a broad wavelength source of light is projected to the
biosensor surface, a particular resonance frequency is established,
governed by the grating structure. The resulting monochromatic
light is reﬂected off of the sensor surface to an imaging
spectrophotometer and the PWV is captured and measured
(Figure 2c). Increases in mass within ~150nm of the sensor
surface, including cultured cells which can be seeded and cultured
on the biosensors, result in a directly proportional positive shift of
the resonant reﬂected PWV. To facilitate neuronal cell growth and
attachment, the biosensor was precoated with poly-ornithine and
laminin, and titration of iNLC number indicated that an optimal
cell density was 18 k cellscm
−2.
To image the iNLCs on the BIND biosensor, we utilized a BIND
Scanner that measures PWV changes on a pixel-by-pixel basis at a
spatial resolution of 3.75×3.75 μm
2, enabling high-contrast
visualization and subsequent segmentation of neuronal morphol-
ogy. As seen from overlays of red ﬂuorescent protein-expressing
iNLCs, the BIND cell adhesion measurement captures neuronal
morphology to a high degree (Figure 2d). The small footprint of
the BIND Scanner allows it to be located within a tissue culture
incubator, enabling high temporal resolution, time-lapse imaging
of cellular responses at physiologic conditions (Figure 2e). As such,
we used this imaging modality in a quantitative assay to measure
changes in cellular morphology and attachment to the biosensor
over the course of 24 h. Examples of sequential images of neurite
outgrowth from plating of the cells on the BIND biosensor are
shown in Figure 1a. We also observed that the neurite outgrowth
tended to follow the linear grating structure of the BIND biosensor
(Figure 2d). From these time-lapse images, we could monitor
growth in terms of area and perimeter of the cells, as well as
extract changes in PWV, a measure of the adhesion of the iNLCs to
the biosensor.
To quantify the cellular phenotypes that could be observed on
the BIND Scanner, we used BIND View software to segment the
BIND scans and compute cell count, cell fraction (fractional area of
the sensor covered by cells), cell perimeter and PWV normalized
by local background. These metrics were averaged over each well
for a given time point with time series over the ﬁrst 5h as shown
in Figure 1b. The most dynamic region of cell growth and
attachment to the surface occurred during the ﬁrst hour after
plating. This is qualitatively seen in the time-lapse videos
(Supplementary Video 1) and time series plots of cell fraction,
cell perimeter and PWV. As we were interested in identifying
phenotypes associated with the temporal dynamics of neuronal
growth and differentiation, we looked at baseline-normalized
changes in the BIND metrics over the time course when cells have
maximally attached. We refer to these as Δcell count, Δcell
fraction, Δcell perimeter and ΔPWV (see Materials and Methods for
more details). Boxplots summarizing the distribution of these
Δmetrics as a function of patient grouping and Alda scale of
lithium responsiveness are shown in Figure 1c.
Statistical analysis of BIND metrics
To model the associations between the BIND Δmetrics and subject
groups, we used generalized linear models (GLMs)
18 with
generalized estimating equations.
19 In addition, we included
adjustments in these models for the following potential con-
founding experimental and clinical variables: the date each plate
was imaged, sex and age. GLMs are similar to general linear
models (for example, multiple regression, ANOVA) but allow
greater ﬂexibility in modeling outcome variables that are non-
normally distributed using alternative distributions (for example,
Poisson or negative binomial) and link functions (for example,
log-transform or logit links). Mixed models using generalized
estimating equation permit the appropriate handling of data
that are hierarchically nested (that is, within subjects and plates)
and thus likely to be correlated; modeling such correlations
ensures appropriate estimation of standard errors and correct
P-values in statistical tests. Further analyses controlled for cell
count as a means of ensuring that observed phenotypes were not
simply a proxy for cell death or segmentation error. Follow-up
analyses utilized the same approach to examine the association
between an ordinal measure of lithium-responsiveness, the Alda
scale and any phenotypes associated with groups in the primary
analysis.
Cellular measurements of iNLCs associated with patient lithium
response
Figure 3a illustrates marginal means and 95% conﬁdence intervals
for each cellular metric, by subject group, drawn from GLM. There
was a signiﬁcant overall difference between patient groups for
ΔPWV (x
2=9.64, P=0.008) but not for Δcell count (x
2=0.93,
P=0.63), Δcell fraction (x
2=2.26, P=0.32) or Δcell perimeter. After
controlling for plate date, sex and age, the signiﬁcant overall
difference between patient groups persisted for ΔPWV (x
2=7.02,
P=0.03) but not for Δcell count (x
2=2.88, P=0.24), Δcell fraction
(x
2=3.54, P=0.17) or Δcell perimeter (x
2=2.45, P=0.29). For
ΔPWV, Bonferroni-corrected post hoc pairwise tests indicated
signiﬁcant differences between BD lithium responsive and
nonresponsive cells (z=2.65, P=0.02); neither group differed
signiﬁcantly from healthy controls (z=−1.48, P=0.42 for controls
(n=6) versus BD lithium nonresponders (n=6) and z=1.36,
P=0.51 for controls versus BD Li responders (n=6)).
Since Δcell count could be used as a measure of segmentation
error and cell death, we incorporated this value into the GLM as an
additional control. The ΔPWV result remained signiﬁcant (Wald’s
test, x
2=10.63, P=0.005), with Bonferroni-corrected post hoc
pairwise differences observed between BD lithium responsive and
nonresponsive (z=3.54, P=0.001) groups. The remaining two
phenotypes Δcell fraction (x
2=3.40, P=0.18) and Δcell perimeter
(x
2=1.00, P=0.61) remained nonsigniﬁcant. The estimated
marginal means derived from the GLM for Δcell fraction, Δcell
perimeter and ΔPWV, corrected for patient age and sex, plate date
and Δcell count, are shown in Figure 3b with 95% conﬁdence
intervals.
We also examined the effects of lithium exposure in the
patients, as this could contribute to the differences in observed
iNLC ΔPWV. In all, ﬁve of six lithium responders, and ﬁve of six
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study enrollment, so lithium exposure in the patients themselves
is unlikely to account for observed differences in iNLC ΔPWV
phenotypes. In GLM models, lithium exposure was not associated
with differential ΔPWV (βΔPWV=0.0009; SE=0.018, P=0.96);
whereas patient group differences remained signiﬁcant
(x
2=70.2, P=0.03) in post hoc pairwise comparison of responders
and nonresponders (z=2.64, P=0.03).
Ordinal measurements of lithium response
In follow-up analysis, we examined association between ΔPWV
and an ordinal measure of lithium response, the Alda scale, rather
than dichotomizing the measure of lithium responsivity. As
anticipated, these models also showed signiﬁcant association
(βΔPWV=0.008; SE=0.003, P=0.008), which persisted with inclu-
sion of Δcell count (βΔPWV=0.009; SE=0.003, P=0.002; Figure 3c).
Taken together, these ﬁndings support the notion that there are
cellular correlates of lithium response in patients that can be
readily monitored and observed in vitro using label-free optical
imaging methodology.
Absence of cellular phenotypes in ﬁbroblasts
Although the primary analyses focused on characterization of
transdifferentiated cells, it is possible that the phenotypes
observed are also present in the cultured ﬁbroblasts.
To address this question, we performed the same BIND measure-
ments and GLM analyses on a subset of the patient ﬁbroblasts
(n=4 healthy controls, n=4 BD lithium responders, n=4 BD
lithium nonresponders). Using a GLM correcting for plate
date, sex and age, we did not observe statistically signiﬁcant
differences in the marginal means for ΔPWV by groups, including
post hoc contrasts between BD lithium responsive and non-
responsive groups (x
2=0.61, P=0.74). Likewise, correcting for
Δcell count did not produce signiﬁcant differences (x
2=0.62,
P=0.73).
Effects of acute lithium treatment
We also investigated the effect of acute lithium exposure on the
BIND phenotypes, by examining lithium at three concentrations
(0.3mM, 0.8mM,1m M) added to the cells at the time of plating on
the biosensor. Once again, GLM models were used to examine
dose effect, correcting for plate date, sex and age. Supplementary
Figure 2 illustrates the PWV measurement by lithium dose (x axis)
and experimental group (color). No signiﬁcant main effects of
treatment were identiﬁed (βΔPWV=0.006; SE=0.005; P=0.24), nor
any evidence of a group-by-treatment interaction (x
2=4.66,
P=0.59).
Figure 1. BIND imaging phenotypes of human iNLCs. (a) BIND images of a representative ﬁeld (scale bar, 100 μm) at 1.2-h intervals beginning
at plating of the cells. Imaging resolution is sufﬁcient to capture outgrowth of cellular processes. (b) Time series quantiﬁcation of BIND
metrics—cell count, cell fraction, perimeter and PWV—over the ﬁrst 4 h of continuous imaging shows that the most dynamic region of cellular
attachment and growth occurs in the ﬁrst 1.5h. (c) Distribution of baseline-normalized changes in BIND metrics for each phenotype, by
patient group. BD, bipolar disorder; iNLC, induced neuronal-like cell; PWV, peak wavelength value.
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In this investigation of 18 patient-derived induced neuron lines,
we identiﬁed a cellular phenotype associated with the lithium
responsiveness of bipolar 1 disorder patients. The phenotype
itself, ΔPWV, can be interpreted as a measure of adhesion of cells
to the biosensor.
13 BD lithium nonresponder cells adhered less
strongly than cells from bipolar patients who respond well to
lithium. Interestingly, cells from control individuals without BD
appeared to be intermediate between lithium-responsive and
nonresponsive BD patient cells. Importantly, no signiﬁcant pheno-
typic differences were observed for this measure in cultured ﬁbro-
blasts, supporting the potential utility of using transdifferen-
tiated cells.
The quantitative metric used in this study, ΔPWV, represents the
change in wavelength of light reﬂected from an optical biosensor
surface. This change in resonant reﬂected light is mediated by
Figure 2. Generation of BD patient-derived iNLCs and BIND imaging. (a) Fibroblasts transduced with miR-9/9*-124, NEUROD2, ASCL1 and MYT1L
undergo selection 3 days after lentiviral infection. RFP expression indicates miR-9/9*-124 expression. Morphological changes occur while cells
are undergoing selection. At 14 days posttransduction, cells have elongated processes resembling neurite outgrowth. (b) Nanostructured
photonic crystal biosensors form the bottom surface of a 384-well plate onto which cells can adhere. Collimated broadband light is projected
onto the biosensor, and the resulting resonant reﬂected light is collected and recorded by an imaging spectrometer, illustrated in c.( d)A n
overlay of the RFP indicator and BIND scan show that detailed morphology of cells can be captured by the BIND scan and is similar to the
morphology seen by ﬂuorescent light microscopy of the RFP indicator. (e) Incubated BIND Scanner allows long-term time-lapse imaging of
iNLCs. BD, bipolar disorder; iNLC, induced neuronal-like cell; RFP, red ﬂuorescent protein.
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extends approximately 200 nm from the sensor surface. Many
different cell types can adhere to optical biosensors coated with
extracellular matrix components that bind to speciﬁc integrins
expressed on the cell surface. The role of integrin–extracellular
matrix interactions on optical biosensors contributing to ΔPWV
measurements has been established in cell lines endogenously
expressing speciﬁc integrins. For example, the human 8866 B cell
line endogenously expresses the α4β7 integrin, which is known to
be a ligand for the extracellular matrix protein, MadCAM.
13 The
addition of 8866 cells to MadCAM-coated biosensors elicits a
strong ΔPWV response whereas a minimal response is measured
when biosensors are coated with a control protein. Furthermore,
the ΔPWV response of 8866 cells on MadCAM-coated sensors is
blocked to completion by an α4-speciﬁc antibody, demonstrating
that the ΔPWV signal is mediated by integrin–CAM interactions.
Similarly, Jurkat cells expressing the α4β1 integrin produce a
ΔPWV signal on optical biosensors coated with VCAM (unpub-
lished results). Speciﬁc inhibitors of the α4β1-VCAM interaction
completely inhibit this signal, as does the addition of EDTA to
chelate divalent cations known to be required for integrin-
mediated cell adhesion. Taken together, these results demonstrate
that the ΔPWV signal is a cell adhesion-mediated measurement
governed by integrin–CAM interactions. The positive shift in the
reﬂected wavelength upon integrin–CAM engagement can be
explained by an increase in cellular mass entering the evanescent
ﬁeld as the cell adheres more strongly to the sensor surface.
Strengths of the present study include a single, clinically-
homogeneous and rigorously phenotyped cohort, including
matched psychiatrically screened healthy controls. Treatment
response was assessed using a validated, gold-standard measure
of lithium responsiveness.
16 Conversely, a key caveat is the
modest effect size observed, and the substantial risk of type 1
error arising in this relatively small cohort. Despite evidence that
lithium response is familial,
15,20,21 the stability of such response
within an individual over time remains to be established.
Furthermore, extrapolating from our cellular observations to
mature neurons is difﬁcult; and although we have shown that
the transformed ﬁbroblasts express structural neuronal markers,
they still comprise a heterogeneous population of cells which
require additional differentiation before they are able to ﬁre action
potentials or form synapses or synapse-like structures.
9 None-
theless, the potential utility of a cell-based model of lithium
response in BD should be apparent, and more generally, a
biomarker for lithium response could have substantial clinical
value, allowing more precise weighing of risks and beneﬁts of
lithium treatment. As one of only two pharmacotherapies in all of
psychiatry was shown to diminish suicide risk,
22 lithium treatment
remains a viable but underused clinical option where the
availability of a biomarker could increase patient and clinician
acceptability.
We did not observe an acute effect of lithium exposure in these
assays. In vitro investigation of lithium remains challenging
because of an apparently narrow therapeutic window (that is,
toxicity at higher doses) as well as a lack of clear correspondence
between in vitro and in vivo lithium levels. We note that, in human
studies in bipolar disorder, lithium may require 6–8 weeks or more
for clinical efﬁcacy, so it is possible that chronic lithium exposure
*
*
Figure 3. Correlation of cellular BIND metrics to clinical features. (a) The four plots illustrate marginal means and 95% conﬁdence intervals for
the four cellular phenotypes identiﬁed using the BIND Scanner, with adjustment for age, sex and experiment. The asterisk denotes a
signiﬁcant difference in ΔPWV between BD Li Non-responders and BD Li Responders as indicated by Bonferroni corrected post hoc pairwise
testing (P=0.02). (b) Marginal means and 95% conﬁdence intervals for change in cell fraction, cell perimeter and PWV, with adjustment for
change in cell count. (c) Results for change in PWV, adjusted as in b, by Alda score (degree of improvement with lithium) group. BD, bipolar
disorder; PWV, peak wavelength value.
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signiﬁcant reduction in cell growth among BD patient cells
compared with healthy controls, which might have been
anticipated based on structural brain imaging showing a decrease
in gray matter volume in the brains of BD patients versus
controls.
23 However, such decreases have been attributed to
oxidative stress-induced apoptosis,
24 something which our cellular
model may not capture.
The cell adhesion phenotype we observed is consistent with
other emerging observations in psychiatric disease models. Cells
derived from schizophrenia patients have been associated with
less adhesion and increased motility,
25 and multiple postmortem
brain studies of psychiatric disease patients show alterations in the
polysialylated neural cell adhesion molecule,
26,27 a protein that
has a key role in cell migration. In addition, genome-wide
association studies of schizophrenia and BD implicate genes
involved in cell adhesion.
28,29
The potential mechanisms by which variation in cell adhesion
could give rise to a connectopathy lies in considering the role that
cell adhesion molecules have in affecting synaptic dynamics and
structural plasticity in neurons. Pathology in the microstructure of
synapses is associated with psychiatric disorders,
30 and the
regulation of synaptic plasticity depends, in large part, on
appropriate functioning of the actin cytoskeleton to support
vesicle cycling and postsynaptic receptors.
31 Recent ﬁndings in a
rodent model have correlated a behavioral phenotype with a
cytoskeletal defect: in particular, a duplication of SHANK3,a
synaptic scaffold and actin-binding protein, was associated with
manic-like behavior similar to the hyperkinetic phenotype of
patients with SHANK3 duplications. Increases in F-actin levels,
mediated through dysregulation of ARP2/3 complexes, which are
central regulators of actin-mediated remodeling and cell motility,
were observed in hippocampal neurons cultured from these
mice.
32 Other lines of evidence have demonstrated that cadherins
and catenins engage in activity-dependent modulation of axon-
–spine contacts.
33 Given that lithium has been demonstrated to
affect neuron growth cones
34 and regulate cytoskeletal dynamics
via GSK3β inhibition,
35 it is suggested that our observed cell
adhesion phenotype may provide an initial step in characterizing
the pathophysiology of BD and efﬁciently screening for novel
therapeutics.
A key advantage of the cellular approach we describe is that it
allows rapid characterization of many cellular phenotypes with a
scalable, label-free platform, making it amenable to high-
throughput chemical screens, RNAi-based screens, large-scale
investigations of genome editing, and potentially, development of
clinical diagnostic tools. The extent of its utility will be clariﬁed by
measurement of phenotypes across disorders and treatments; at
minimum, it should facilitate efforts to elucidate mechanism of
action of the gold-standard treatment for a disorder that
contributes substantially to morbidity from psychiatric disease
worldwide.
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